Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
ConclusionThis large-scale PMS study demonstrated that regdanvimab was effective against COVID-19 progression and had an acceptable safety profile when used in real-world clinical practice. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 13, 2023 Category: Infectious Diseases Source Type: research
Characterization of a Tigecycline-, Linezolid- and Vancomycin-Resistant Clinical Enteroccoccus faecium Isolate, Carrying vanA and vanB Genes
ConclusionsWe provide the detailed characteristics of the genomic determinants of antimicrobial resistance of a clinicalE. faecium demonstrating the concomitant presence of bothvanA andvanB and resistance to vancomycin, linezolid, tigecycline and several other compounds and decreased daptomycin susceptibility. This isolate is a striking example of an accumulation of resistance determinants involving various mechanisms by a single hospital strain. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 11, 2023 Category: Infectious Diseases Source Type: research
The Present and Future Aspects of Life-Long Pertussis Prevention: Narrative Review with Regional Perspectives for T ürkiye
AbstractPertussis, caused byBordetella pertussis, remains one of the most widespread, contagious, and vaccine-preventable diseases. It results in notable morbidity and mortality as well as severe medical, social, and economic burden. Despite high global vaccine coverage, pertussis continues to be a significant epidemiologic problem, with outbreak episodes every few years just as in the pre-vaccination era. In T ürkiye, there is a lack of comprehensive data on the current burden of pertussis in different age and risk groups, leading to underdiagnosis and underreporting of the disease, especially in adults who are often not...
Source: Infectious Diseases and Therapy - October 10, 2023 Category: Infectious Diseases Source Type: research
The Causal Impact of the Gut Microbiota on Respiratory Tuberculosis Susceptibility
ConclusionThis research sheds light on the causal impact of gut microbiota on respiratory tuberculosis susceptibility, improving our knowledge of therapeutic strategies for managing TB. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 10, 2023 Category: Infectious Diseases Source Type: research
The Present and Future Aspects of Life-Long Pertussis Prevention: Narrative Review with Regional Perspectives for T ürkiye
AbstractPertussis, caused byBordetella pertussis, remains one of the most widespread, contagious, and vaccine-preventable diseases. It results in notable morbidity and mortality as well as severe medical, social, and economic burden. Despite high global vaccine coverage, pertussis continues to be a significant epidemiologic problem, with outbreak episodes every few years just as in the pre-vaccination era. In T ürkiye, there is a lack of comprehensive data on the current burden of pertussis in different age and risk groups, leading to underdiagnosis and underreporting of the disease, especially in adults who are often not...
Source: Infectious Diseases and Therapy - October 10, 2023 Category: Infectious Diseases Source Type: research
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study
ConclusionRemdesivir generally does not increase the incidence of rapid clinical improvement in hospitalised patients with COVID-19, but it might have an effect in patients with short duration of symptoms and limited signs of systemic inflammation. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 6, 2023 Category: Infectious Diseases Source Type: research
Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
ConclusionsDalbavancin inoculum effect is a major issue in bacterial infections with high bacterial loads and the combination of DAL plus single dose of DAP showed promise in eradicating resistantS. aureus strains at high inoculums. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 5, 2023 Category: Infectious Diseases Source Type: research
Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study
ConclusionsThis trial did not meet the primary efficacy endpoints, yet reparixin showed a trend toward limiting disease progression as an add-on therapy in COVID-19 severe pneumonia and was well tolerated.Trial RegistrationClinicalTrials.gov: NCT04878055, EudraCT: 2020-005919-51.Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 5, 2023 Category: Infectious Diseases Source Type: research
Correction to: Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 4, 2023 Category: Infectious Diseases Source Type: research
Pharmacokinetics and Safety of Ainuovirine/Lamivudine/Tenofovir Combination Tablets in Young and Elderly Patients with Human Immunodeficiency Virus-1 Infection
ConclusionThis study suggests that the ainuovirine/lamivudine/tenofovir regimen might be an effective and safe treatment regimen for HIV-1-infected patients aged ≥ 65 years and ≤ 40 years. Further studies are needed to confirm these results and develop optimal dosing regimens for elderly HIV-1-infected patients. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 3, 2023 Category: Infectious Diseases Source Type: research
Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
ConclusionThis large-scale PMS study demonstrated that regdanvimab was effective against COVID-19 progression and had an acceptable safety profile when used in real-world clinical practice. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 1, 2023 Category: Infectious Diseases Source Type: research
